BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37301739)

  • 21. Time to Triple Therapy in Patients With de Novo Heart Failure With Reduced Ejection Fraction: a Population-Based Study.
    Sepehrvand N; Nabipoor M; Youngson E; McAlister FA; Ezekowitz JA
    J Card Fail; 2023 May; 29(5):719-729. PubMed ID: 36754252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of guideline-based cardiovascular medications and their respective doses in heart failure patients in Oman.
    Hanbali DA; Hashmi KA; Za'abi MA; Al-Zakwani I
    Int J Clin Pharm; 2021 Aug; 43(4):878-883. PubMed ID: 33140296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Individual Patient Profiles on Adherence to Guideline Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction: VCOR-HF Study.
    Driscoll A; Dinh D; Wong J; Hopper I; Mariani J; Zimmet H; Brennan A; Lefkovits J; Carruthers H; Reid CM
    Heart Lung Circ; 2020 Dec; 29(12):1782-1789. PubMed ID: 32646638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guideline-directed therapy at discharge in patients with heart failure and atrial fibrillation.
    Ahn MS; Yoo BS; Yoon J; Lee SH; Kim JY; Ahn SG; Youn YJ; Lee JW; Son JW; Kim HS; Kang DR; Cho HJ; Lee HY; Jeon ES; Kang SM; Choi DJ; Cho MC
    Heart; 2020 Feb; 106(4):292-298. PubMed ID: 31492703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry.
    Chang HY; Wang CC; Wei J; Chang CY; Chuang YC; Huang CL; Chong E; Lin JL; Mar GY; Chan KC; Kuo JY; Wang JH; Chen ZC; Tseng WK; Cherng WJ; Yin WH
    J Chin Med Assoc; 2017 Dec; 80(12):750-757. PubMed ID: 29033112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management, clinical outcomes, and its predictors among heart failure patients admitted to tertiary care hospitals in Ethiopia: prospective observational study.
    Beri B; Fanta K; Bekele F; Bedada W
    BMC Cardiovasc Disord; 2023 Jan; 23(1):4. PubMed ID: 36609240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
    Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
    Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation.
    Ahn MS; Yoo BS; Son JW; Park YJ; Lee HY; Jeon ES; Kang SM; Choi DJ; Kim KH; Cho MC; Kim SY; Kang DR; Go TH
    J Korean Med Sci; 2021 Oct; 36(40):e252. PubMed ID: 34664798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction.
    Driscoll A; Currey J; Tonkin A; Krum H
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD009889. PubMed ID: 26689943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Optimizing Guideline-Directed Medical Therapy Before Discharge on Mortality and Heart Failure Readmission in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
    Yamaguchi T; Kitai T; Miyamoto T; Kagiyama N; Okumura T; Kida K; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Yamaguchi J; Iwai T; Hijikata S; Masuda R; Miyazaki R; Hara N; Nagata Y; Nozato T; Matsue Y
    Am J Cardiol; 2018 Apr; 121(8):969-974. PubMed ID: 29477488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M
    JAMA; 2012 Nov; 308(20):2108-17. PubMed ID: 23188027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of guideline-consistent heart failure drug prescriptions at hospital discharge on 1-year mortality: Results from the EPICAL2 cohort study.
    Busson A; Thilly N; Laborde-Castérot H; Alla F; Messikh Z; Clerc-Urmes I; Mebazaa A; Soudant M; Agrinier N
    Eur J Intern Med; 2018 May; 51():53-60. PubMed ID: 29305071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence-Based Process Performance Measures and Clinical Outcomes in Patients With Incident Heart Failure With Reduced Ejection Fraction: A Danish Nationwide Cohort Study.
    Schjødt I; Johnsen SP; Strömberg A; DeVore AD; Valentin JB; Løgstrup BB
    Circ Cardiovasc Qual Outcomes; 2022 Apr; 15(4):e007973. PubMed ID: 35272503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacological therapy of heart failure with reduced ejection fraction].
    Wieser M; Rhyner D; Martinelli M; Suter T; Schnegg B; Bösch C; Wigger O; Dobner S; Hunziker L
    Ther Umsch; 2018 Sep; 75(3):180-186. PubMed ID: 30145973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
    Sandhu AT; Kohsaka S; Turakhia MP; Lewis EF; Heidenreich PA
    JAMA Cardiol; 2022 Feb; 7(2):130-139. PubMed ID: 34757380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
    Verma S; Dhingra NK; Butler J; Anker SD; Ferreira JP; Filippatos G; Januzzi JL; Lam CSP; Sattar N; Peil B; Nordaby M; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Lancet Diabetes Endocrinol; 2022 Jan; 10(1):35-45. PubMed ID: 34861154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.
    Güder G; Störk S; Gelbrich G; Brenner S; Deubner N; Morbach C; Wallenborn J; Berliner D; Ertl G; Angermann CE
    Eur J Heart Fail; 2015 Apr; 17(4):442-52. PubMed ID: 25727879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction.
    Veenis JF; Rocca HB; Linssen GCM; Erol-Yilmaz A; Pronk ACB; Engelen DJM; van Tooren RM; Koornstra-Wortel HJJ; de Boer RA; van der Meer P; Hoes AW; Brugts JJ;
    Eur J Prev Cardiol; 2021 Aug; 28(9):957-965. PubMed ID: 34402878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.
    Santema BT; Ouwerkerk W; Tromp J; Sama IE; Ravera A; Regitz-Zagrosek V; Hillege H; Samani NJ; Zannad F; Dickstein K; Lang CC; Cleland JG; Ter Maaten JM; Metra M; Anker SD; van der Harst P; Ng LL; van der Meer P; van Veldhuisen DJ; Meyer S; Lam CSP; ; Voors AA
    Lancet; 2019 Oct; 394(10205):1254-1263. PubMed ID: 31447116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.